phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"phgenomics-160Research ArticleМНЕНИЕ ЭКСПЕРТАEXPERT OPINIONТрансляционная медицина: новая надежда или коварный замысел фармацевтической промышленности?Translational medicine: new hope or artful design of big pharma?АшихминЯ. И.AshikhminY. I.

Ашихмин Ярослав Игоревич — к.м.н., кардиолог.

г. Москва

Moscow

ya.ashikhmin@gmail.comФГБУ «Лечебно-реабилитационный центр» Минздрава РоссииРоссияFGBI «Medical and Rehabilitation Center» Ministry of Health RFRussian Federation201524032020014044Copyright © Ашихмин Я.И., 20202020Ашихмин Я.И.Ashikhmin Y.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/160

Обзор посвящён трансляционной медицине как новому интегративному подходу к созданию новых медицинских технологий. Освещены общие аспекты и механизмы реализации методологии трансляционной медицины в конкретных биомедицинских исследованиях.

This review is devoted to translational medicine as novel integrative approach for novel treatment development. Basic aspects and mechanisms of implementation of translational medicine armamentarium in certain biomedical researches are addressed.

трансляционная медицинатрансляционный подходсоздание новых лекарственных препаратовклинические исследованияtranslational medicinetranslational researchfrom bench to bedsidedrug developmentclinical trialsReferencesFitzGerald G. Anticipating change in drug development: the emerging era of translational medicine and therapeutics // Nat Rev Drug Discov. 2005 Oct;4(10):815-8.FitzGerald G. Anticipating change in drug development: the emerging era of translational medicine and therapeutics // Nat Rev Drug Discov. 2005 Oct;4(10):815-8.http://government.ru/docs/16428/.http://government.ru/docs/16428/.http://www.fda.gov/drugs/drugsafety/ucm264059.htm.http://www.fda.gov/drugs/drugsafety/ucm264059.htm.http://www.forbes.com/sites/matthewherper/2013/06/06/what-the-fdas-avandia-decision-means-for-the-future/.http://www.forbes.com/sites/matthewherper/2013/06/06/what-the-fdas-avandia-decision-means-for-the-future/.http://www.oecd.org/sti/biotech/35641467.pdf.http://www.oecd.org/sti/biotech/35641467.pdf.https://clinicaltrials.gov/ct2/show/NCT01643590?term=STOP-HF&rank=2.https://clinicaltrials.gov/ct2/show/NCT01643590?term=STOP-HF&rank=2.https://en.wikipedia.org/wiki/ApoA-1_Milano.https://en.wikipedia.org/wiki/ApoA-1_Milano.Mankoff S., Brander C., Ferrone S., Marincola F. Lost in Translation: Obstacles to Translational Medicine. // Journal of Translational Medicine 2004, 2:14.Mankoff S., Brander C., Ferrone S., Marincola F. Lost in Translation: Obstacles to Translational Medicine. // Journal of Translational Medicine 2004, 2:14.Namsolleck P., Recarti C., Foulquier S. AT2 Receptor and Tissue Injury: Therapeutic Implications. // Curr Hypertens Rep. 2014; 16(2): 416.Namsolleck P., Recarti C., Foulquier S. AT2 Receptor and Tissue Injury: Therapeutic Implications. // Curr Hypertens Rep. 2014; 16(2): 416.Schwartz G., Olsson A., Abt M. et al. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. // N Engl J Med 2012; 367:2089-2099.Schwartz G., Olsson A., Abt M. et al. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. // N Engl J Med 2012; 367:2089-2099.Seals D. Translational physiology: from molecules to public health. // J Physiol 591.14 (2013) pp 3457—3469.Seals D. Translational physiology: from molecules to public health. // J Physiol 591.14 (2013) pp 3457—3469.Strauss M. Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. Unraveling the ARB-MI Paradox. // Circulation. 2006; 114: 838-854.Strauss M. Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. Unraveling the ARB-MI Paradox. // Circulation. 2006; 114: 838-854.Tall A., Yvan-Charvet L., Wang N. The Failure of Torcetrapib. Was it the Molecule or the Mechanism? // Arteriosclerosis, Thrombosis, and Vascular Biology. 2007; 27: 257-260.Tall A., Yvan-Charvet L., Wang N. The Failure of Torcetrapib. Was it the Molecule or the Mechanism? // Arteriosclerosis, Thrombosis, and Vascular Biology. 2007; 27: 257-260.

The authors declare that there are no conflicts of interest present.